Junichi Takada
Research Subjects
Junichi Takada has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Kousuke Iba
Sapporo Bone and Hand Surgery Institute, Sapporo Minami Orthopaedic Hospital, Sapporo, Japan
15 shared publications Toshihiko Yamashita
14 shared publicationsTakashi Yoshizaki
Kitago Orthopaedic Clinic, Sapporo, Japan
6 shared publicationsKousuke Iba
Department of Orthopedic Surgery, Sapporo Medical University, Sapporo, Japan
3 shared publications- Takuro Wada
Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
3 shared publications Tomohiro Akatsuka
Sapporo Kotoni Orthopaedic, Sapporo, Japan
3 shared publications
Latest Publications
- 23 September 2025
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 43 (6) , 728-729
Author’s response to letter to the editor: Re: Probability of achieving treatments goals with twice-weekly teriparatide followed by bisphosphonate in Japanese postmenopausal osteoporosis
We appreciate the valuable suggestions and comments that Drs. Caroline Francis, Koyel Roy, and Gujar Anantkumar Jotiram provided regarding this study, "Probability of Achieving Treatment Goals with Twice-Weekly Teriparatide Followed by Bisphosphonate in Japanese Postmenopausal Osteoporosis".
- 23 September 2025
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 43 (6) , 728-729
Author’s response to letter to the editor: Re: Probability of achieving treatments goals with twice-weekly teriparatide followed by bisphosphonate in Japanese postmenopausal osteoporosis
We appreciate the valuable suggestions and comments that Drs. Caroline Francis, Koyel Roy, and Gujar Anantkumar Jotiram provided regarding this study, "Probability of Achieving Treatment Goals with Twice-Weekly Teriparatide Followed by Bisphosphonate in Japanese Postmenopausal Osteoporosis".
- 15 July 2025
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 43 (5) , 564-572
Probability of achieving treatments goals with twice-weekly teriparatide followed by bisphosphonate in Japanese postmenopausal osteoporosis
Introduction The purpose of this study is to evaluate the increase in bone mineral density (BMD) and achievement of treatment goals based on the ASBMR/BHOF position statement over 3 years of sequential therapy with 2 years of twice-weekly teriparatide (2/W TPTD) followed by 1 year of bisphosphonate (BP) therapy. Materials and methods This was a multicenter, retrospective study. Thirty-eight postmenopausal patients with primary osteoporosis at very high risk of fracture according to the Diagnostic Criteria for Primary Osteoporosis in Japan were enrolled. Changes in BMD at the lumbar spine (LS) and total hip (TH) were evaluated. Patients were divided into the naïve group (no history of osteoporosis treatment) and the pre-BP group (prior BP treatment). The treatment goals were assessed using the BMD T-score as follows; Baseline T-score ≤ − 2.5: Greater than − 2.5 at 3 years and baseline T-score > − 2.5: Increase at least 0.5 for LS and 0.2 for TH. Results The naïve group showed a significant increase in LS-BMD and TH-BMD of 14.6% and 4.8%, respectively, and the pre-BP group only showed a significant increase in LS-BMD of 8.4% over 3 years. In the naïve group, 60.7% (17/28) achieved the treatment goal for LS-BMD, and 39.3% (11/28) achieved for TH-BMD. In the pre-BP group, 50.0% (4/8) achieved the treatment goal for LS-BMD, but no patient achieved the goal for TH-BMD. Conclusion After 3 years of sequential therapy from 2/W TPTD to BP, 50% or more of the patients achieved the treatment goal in the LS-BMD but not in the TH-BMD.
- 15 July 2025
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 43 (5) , 564-572
Probability of achieving treatments goals with twice-weekly teriparatide followed by bisphosphonate in Japanese postmenopausal osteoporosis
Introduction The purpose of this study is to evaluate the increase in bone mineral density (BMD) and achievement of treatment goals based on the ASBMR/BHOF position statement over 3 years of sequential therapy with 2 years of twice-weekly teriparatide (2/W TPTD) followed by 1 year of bisphosphonate (BP) therapy. Materials and methods This was a multicenter, retrospective study. Thirty-eight postmenopausal patients with primary osteoporosis at very high risk of fracture according to the Diagnostic Criteria for Primary Osteoporosis in Japan were enrolled. Changes in BMD at the lumbar spine (LS) and total hip (TH) were evaluated. Patients were divided into the naïve group (no history of osteoporosis treatment) and the pre-BP group (prior BP treatment). The treatment goals were assessed using the BMD T-score as follows; Baseline T-score ≤ − 2.5: Greater than − 2.5 at 3 years and baseline T-score > − 2.5: Increase at least 0.5 for LS and 0.2 for TH. Results The naïve group showed a significant increase in LS-BMD and TH-BMD of 14.6% and 4.8%, respectively, and the pre-BP group only showed a significant increase in LS-BMD of 8.4% over 3 years. In the naïve group, 60.7% (17/28) achieved the treatment goal for LS-BMD, and 39.3% (11/28) achieved for TH-BMD. In the pre-BP group, 50.0% (4/8) achieved the treatment goal for LS-BMD, but no patient achieved the goal for TH-BMD. Conclusion After 3 years of sequential therapy from 2/W TPTD to BP, 50% or more of the patients achieved the treatment goal in the LS-BMD but not in the TH-BMD.
- 2 July 2024
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 19 (1) , 55
Effects of differences in dose and frequency of teriparatide on bone structure in Proximal Femur. – Analysis by DXA-based 3D-modeling (3D-SHAPER Software) –TRIPLE-BONE study (The effects of TeRIParatide preparation on bone mineraL density increase and BONE structure)
Trends toward more favorable improvement of the cortical bone parameters by once-weekly (56.5 mu g once a week) and twice-weekly teriparatide (28.2 mu g twice a week), and that of the trabecular bone parameters by once-daily (1/D) teriparatide (20 mu g/day once a day) were shown. Purpose To examine the effects of differences in the amount of teriparatide (TPTD) per administration and its dosing frequency on the bone structure in the proximal femur by dual-energy X-ray absorptiometry (DXA)-based 3D-modeling (3D-SHAPER software). Methods This was a multicenter retrospective study. Patients aged 50 years or older with primary osteoporosis who continuously received once-/twice-weekly (1.2/W, n = 60) or 1/D TPTD (n = 14) administration for at least one year were included in the study. Measurement regions included the femoral neck (FN), trochanter (TR), femoral shaft (FS), and total proximal hip (TH). Concurrently, the bone mineral density (BMD) and Trabecular Bone Score (TBS) were measured. Results The cross-sectional area, cross-sectional moment of inertia, and section modulus in the FS were significantly improved in the 1.2/W TPTD group, as compared to the 1/D TPTD group. However, significant improvement of the cortical thickness and buckling ratio in the FN was observed in the 1/D TPTD group, as compared to the 1.2/W TPTD group. Trabecular BMD values in the FS and TH were significantly increased in the 1/D TPTD group, as compared to the 1.2/W TPTD group, while the cortical BMD values in the TR, FS, and TH were significantly increased in the 1.2/W TPTD group, as compared to the 1/D TPTD group. ConclusionTrends toward more favorable improvement of the cortical bone by 1.2/W TPTD and that of the trabecular bones by 1/D TPTD were observed.
- 2 July 2024
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 19 (1) , 55
Effects of differences in dose and frequency of teriparatide on bone structure in Proximal Femur. – Analysis by DXA-based 3D-modeling (3D-SHAPER Software) –TRIPLE-BONE study (The effects of TeRIParatide preparation on bone mineraL density increase and BONE structure)
Trends toward more favorable improvement of the cortical bone parameters by once-weekly (56.5 mu g once a week) and twice-weekly teriparatide (28.2 mu g twice a week), and that of the trabecular bone parameters by once-daily (1/D) teriparatide (20 mu g/day once a day) were shown. Purpose To examine the effects of differences in the amount of teriparatide (TPTD) per administration and its dosing frequency on the bone structure in the proximal femur by dual-energy X-ray absorptiometry (DXA)-based 3D-modeling (3D-SHAPER software). Methods This was a multicenter retrospective study. Patients aged 50 years or older with primary osteoporosis who continuously received once-/twice-weekly (1.2/W, n = 60) or 1/D TPTD (n = 14) administration for at least one year were included in the study. Measurement regions included the femoral neck (FN), trochanter (TR), femoral shaft (FS), and total proximal hip (TH). Concurrently, the bone mineral density (BMD) and Trabecular Bone Score (TBS) were measured. Results The cross-sectional area, cross-sectional moment of inertia, and section modulus in the FS were significantly improved in the 1.2/W TPTD group, as compared to the 1/D TPTD group. However, significant improvement of the cortical thickness and buckling ratio in the FN was observed in the 1/D TPTD group, as compared to the 1.2/W TPTD group. Trabecular BMD values in the FS and TH were significantly increased in the 1/D TPTD group, as compared to the 1.2/W TPTD group, while the cortical BMD values in the TR, FS, and TH were significantly increased in the 1.2/W TPTD group, as compared to the 1/D TPTD group. ConclusionTrends toward more favorable improvement of the cortical bone by 1.2/W TPTD and that of the trabecular bones by 1/D TPTD were observed.
- Open Access
- 20 March 2020
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 38 (4) , 605
Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
In the original publication of the article, the last row of Table 1 was published incorrectly as “Serum P1NP (μmol/L), median (IQR)b : Romo
- 20 March 2020
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 38 (4) , 605
Open AccessCorrection to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
In the original publication of the article, the last row of Table 1 was published incorrectly as “Serum P1NP (μmol/L), median (IQR)b : Romo
- 9 November 2019
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 38 (3) , 310-315
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
Procollagen type I N-terminal propeptide (P1NP), a bone formation marker, reportedly predicts bone mineral density (BMD) response to teriparatide treatment in treatment-naive patients with osteoporosis. Results from a randomized, phase 3, open-label, active-controlled trial— STRUCTURE—showed that in patients previously treated with bisphosphonates, romosozumab led to gains in hip BMD, which were not observed with teriparatide. This post hoc analysis investigated the comparative utility of early changes in P1NP in predicting BMD response in patients who participated in the STRUCTURE trial, which enrolled patients who switched treatment from bisphosphonates to romosozumab/teriparatide.
- 9 November 2019
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 38 (3) , 310-315
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
Procollagen type I N-terminal propeptide (P1NP), a bone formation marker, reportedly predicts bone mineral density (BMD) response to teriparatide treatment in treatment-naive patients with osteoporosis. Results from a randomized, phase 3, open-label, active-controlled trial— STRUCTURE—showed that in patients previously treated with bisphosphonates, romosozumab led to gains in hip BMD, which were not observed with teriparatide. This post hoc analysis investigated the comparative utility of early changes in P1NP in predicting BMD response in patients who participated in the STRUCTURE trial, which enrolled patients who switched treatment from bisphosphonates to romosozumab/teriparatide.
- Open Access
- 19 December 2016
- Published by SAGE Publications in Journal of Orthopaedic Surgery
- Vol. 24 (3) , 362-366
Combined Use of Ibandronate and Eldecalcitol in Postmenopausal Japanese Women with Osteoporosis
Purpose: To evaluate the effect of combined use of ibandronate and eldecalcitol for 6 to 12 months on bone mineral density (BMD) and bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis. Methods: BMD and bone strength of the proximal femur were evaluated in 78 postmenopausal women (mean age, 73.6 years) who underwent treatment for osteoporosis with combined use of ibandronate and eldecalcitol for at least 6 months. BMD was measured at the lumbar spine, femoral neck, and total hip using dual-energy X-ray absorptiometry (DXA) at baseline and every 6 months thereafter. Hip structure analysis of the narrow neck and intertrochanter was performed by a radiologist using DXA images. Results: Respectively for the lumbar spine, femoral neck, and total hip, BMD significantly increased (from baseline) by 4.54%, 2.31%, and 1.56% at 6 months and by 5.92%, 3.02%, and 2.70% at 12 months. In hip structure analysis, most parameters improved significantly. Respectively for the narrow neck and intertrochanter, BMD significantly increased (from baseline) by 2.37% and 2.71% at 6 months and by 3.46% and 3.52% at 12 months; cross-sectional area significantly increased by 1.83% and 3.39% at 6 months and by 2.91% and 3.46% at 12 months; section modulus significantly increased by 2.42% and 4.11% at 6 months and by 4.84% and 3.26% at 12 months; cortical thickness significantly increased by 2.49% and 3.33% at 6 months and by 3.73% and 3.37% at 12 months; and buckling ratio significantly decreased by 2.97% and 2.57% at 6 months and by 3.86% and 2.99% at 12 months. Conclusion: Combined use of ibandronate and eldecalcitol for 6 months significantly improved bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.
- 19 December 2016
- Published by SAGE Publications in Journal of Orthopaedic Surgery
- Vol. 24 (3) , 362-366
Open AccessCombined Use of Ibandronate and Eldecalcitol in Postmenopausal Japanese Women with Osteoporosis
Purpose: To evaluate the effect of combined use of ibandronate and eldecalcitol for 6 to 12 months on bone mineral density (BMD) and bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis. Methods: BMD and bone strength of the proximal femur were evaluated in 78 postmenopausal women (mean age, 73.6 years) who underwent treatment for osteoporosis with combined use of ibandronate and eldecalcitol for at least 6 months. BMD was measured at the lumbar spine, femoral neck, and total hip using dual-energy X-ray absorptiometry (DXA) at baseline and every 6 months thereafter. Hip structure analysis of the narrow neck and intertrochanter was performed by a radiologist using DXA images. Results: Respectively for the lumbar spine, femoral neck, and total hip, BMD significantly increased (from baseline) by 4.54%, 2.31%, and 1.56% at 6 months and by 5.92%, 3.02%, and 2.70% at 12 months. In hip structure analysis, most parameters improved significantly. Respectively for the narrow neck and intertrochanter, BMD significantly increased (from baseline) by 2.37% and 2.71% at 6 months and by 3.46% and 3.52% at 12 months; cross-sectional area significantly increased by 1.83% and 3.39% at 6 months and by 2.91% and 3.46% at 12 months; section modulus significantly increased by 2.42% and 4.11% at 6 months and by 4.84% and 3.26% at 12 months; cortical thickness significantly increased by 2.49% and 3.33% at 6 months and by 3.73% and 3.37% at 12 months; and buckling ratio significantly decreased by 2.97% and 2.57% at 6 months and by 3.86% and 2.99% at 12 months. Conclusion: Combined use of ibandronate and eldecalcitol for 6 months significantly improved bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.
- 1 January 2016
- Published by Edikta s.r.l. in Bone Abstracts
- Vol. 13 (1) , 25-8
Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis
This study analyzes whether concomitant raloxifene (RLX) or bisphosphonates (BP) plus eldecalcitol (ELD) has excessive suppressive effects on a bone resorption marker during the first 6 months of treatment in postmenopausal women in real-world setting. 285 postmenopausal osteoporotic patients who had been treated with RLX or BP plus ELD were evaluated the bone resorption marker, serum tartrate resistant acid phosphatase-5b (TRACP-5b), during the first 6 months of treatment. In drug-naïve group (not received osteoporosis medications before the administration, n=70), the concomitant RLX or BP with ELD significantly decreased levels of TRACP-5b without severe suppression. In vitamin D switch group [RLX or BP plus alfacalcidol (ALF) and then switched to RLX or BP plus ELD, n=215], the replacing ALF with ELD further and significantly decreased TRACP-5b and tertile analyses based on baseline values were significantly decreased far more in the highest, compared with the lowest tertile in the ELD+RLX and ELD+BP groups. ELD combined with RLX or BP administered for 6 months to postmenopausal women with osteoporosis who were drug-naïve or who had switched medications significantly reduced and maintained TRACP-5b values within the reference range.
- 1 January 2016
- Published by Edikta s.r.l. in Bone Abstracts
- Vol. 13 (1) , 25-8
Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis
This study analyzes whether concomitant raloxifene (RLX) or bisphosphonates (BP) plus eldecalcitol (ELD) has excessive suppressive effects on a bone resorption marker during the first 6 months of treatment in postmenopausal women in real-world setting. 285 postmenopausal osteoporotic patients who had been treated with RLX or BP plus ELD were evaluated the bone resorption marker, serum tartrate resistant acid phosphatase-5b (TRACP-5b), during the first 6 months of treatment. In drug-naïve group (not received osteoporosis medications before the administration, n=70), the concomitant RLX or BP with ELD significantly decreased levels of TRACP-5b without severe suppression. In vitamin D switch group [RLX or BP plus alfacalcidol (ALF) and then switched to RLX or BP plus ELD, n=215], the replacing ALF with ELD further and significantly decreased TRACP-5b and tertile analyses based on baseline values were significantly decreased far more in the highest, compared with the lowest tertile in the ELD+RLX and ELD+BP groups. ELD combined with RLX or BP administered for 6 months to postmenopausal women with osteoporosis who were drug-naïve or who had switched medications significantly reduced and maintained TRACP-5b values within the reference range.
- 1 July 2013
- Vol. 23 (7) , 1041-8
[The changes in bone geometric parameters by medication].
The changes in bone geometric parameters (hip structure analysis, HSA) by medication are reviewed. HSA parameters are strongly correlated with CT parameters. Raloxifene, bisphosphonate (alendronate, risedronate, minodronate) , and denosumab improved section modulus (index for bending force) more than bone mineral density, and the improvements in section modulus are superior in intertrochanter than in femoral neck. The tendency to change in femoral shaft is approximately similar in femoral neck and intertrochanter. On the other hand, the tendency to change in these parameters in teriparatide (20μg/day) is different from raloxifene, bisphosphonate, and denosumab. Teriparatide improved section modulus and bone mineral density in femoral neck and intertrochanter, but the improvement in section modulus was approximately similar in bone mineral density and the improvement in intertrochanter is not higher than femoral neck. The femoral shaft did not show significant change.
- 1 July 2013
- Vol. 23 (7) , 1041-8
[The changes in bone geometric parameters by medication].
The changes in bone geometric parameters (hip structure analysis, HSA) by medication are reviewed. HSA parameters are strongly correlated with CT parameters. Raloxifene, bisphosphonate (alendronate, risedronate, minodronate) , and denosumab improved section modulus (index for bending force) more than bone mineral density, and the improvements in section modulus are superior in intertrochanter than in femoral neck. The tendency to change in femoral shaft is approximately similar in femoral neck and intertrochanter. On the other hand, the tendency to change in these parameters in teriparatide (20μg/day) is different from raloxifene, bisphosphonate, and denosumab. Teriparatide improved section modulus and bone mineral density in femoral neck and intertrochanter, but the improvement in section modulus was approximately similar in bone mineral density and the improvement in intertrochanter is not higher than femoral neck. The femoral shaft did not show significant change.
- Open Access
- 1 August 2012
- Published by SAGE Publications in Journal of Orthopaedic Surgery
- Vol. 20 (2) , 209-213
Correlation between a Bone Resorption Marker and Structural Geometry of the Proximal Femur in Osteoporotic Women Treated with Raloxifene
To assess correlations between a bone resorption marker and the structural geometry of the proximal femur in raloxifene-treated postmenopausal women with osteoporosis. 45 postmenopausal, osteoporotic women aged 57 to 79 (mean, 67) years underwent raloxifene treatment (60 mg/day) for 12 months. Serum type-I collagen crosslinked N-telopeptide (sNTX) as the bone resorption marker was measured at baseline and 6 months, whereas hip structure analysis (HSA) parameters of the femur (neck, intertrochanter, and shaft) were measured at baseline and 12 months using dual energy X-ray absorptiometry. The HSA parameters included areal bone mineral density (BMD), inner diameter, mean cortical thickness, cross-sectional area, section modulus, and buckling ratio. Correlations between sNTX and HSA parameters were analysed using Pearson's R. At baseline, sNTX correlated inversely with BMD, cross-sectional area, mean cortical thickness, and section modulus, and positively with buckling ratio in the intertrochanter and shaft (but not the neck). These correlations were significant both crude and adjusted for age. After 12 months of raloxifene treatment, HSA parameters improved significantly for the intertrochanter and shaft only. Of the 3 femoral sites, only the change in sNTX at month 6 correlated positively with changes in the inner diameter at the intertrochanter at month 12 (r=0.303, p=0.045 adjusted for age). Changes in sNTX did not correlate with changes in any other parameters. The surrogate markers for hip fracture including sNTX, BMD, and HSA parameters correlated significantly with each other. Improvement (decrease) of sNTX indicated reduction in bone resorption.
- 1 August 2012
- Published by SAGE Publications in Journal of Orthopaedic Surgery
- Vol. 20 (2) , 209-213
Open AccessCorrelation between a Bone Resorption Marker and Structural Geometry of the Proximal Femur in Osteoporotic Women Treated with Raloxifene
To assess correlations between a bone resorption marker and the structural geometry of the proximal femur in raloxifene-treated postmenopausal women with osteoporosis. 45 postmenopausal, osteoporotic women aged 57 to 79 (mean, 67) years underwent raloxifene treatment (60 mg/day) for 12 months. Serum type-I collagen crosslinked N-telopeptide (sNTX) as the bone resorption marker was measured at baseline and 6 months, whereas hip structure analysis (HSA) parameters of the femur (neck, intertrochanter, and shaft) were measured at baseline and 12 months using dual energy X-ray absorptiometry. The HSA parameters included areal bone mineral density (BMD), inner diameter, mean cortical thickness, cross-sectional area, section modulus, and buckling ratio. Correlations between sNTX and HSA parameters were analysed using Pearson's R. At baseline, sNTX correlated inversely with BMD, cross-sectional area, mean cortical thickness, and section modulus, and positively with buckling ratio in the intertrochanter and shaft (but not the neck). These correlations were significant both crude and adjusted for age. After 12 months of raloxifene treatment, HSA parameters improved significantly for the intertrochanter and shaft only. Of the 3 femoral sites, only the change in sNTX at month 6 correlated positively with changes in the inner diameter at the intertrochanter at month 12 (r=0.303, p=0.045 adjusted for age). Changes in sNTX did not correlate with changes in any other parameters. The surrogate markers for hip fracture including sNTX, BMD, and HSA parameters correlated significantly with each other. Improvement (decrease) of sNTX indicated reduction in bone resorption.
- Open Access
- 4 August 2011
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 5 (1) , 349
Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series
Introduction: Complex regional pain syndrome is characterized by pain, allodynia, hyperalgesia, edema, signs of vasomotor instability, movement disorders, joint stiffness, and regional osteopenia. It is recognized to be difficult to treat, despite various methods of treatment, including physiotherapy, calcitonin, corticosteroids, sympathetic blockade, and nonsteroidal anti-inflammatory drugs. Pathophysiologically, complex regional pain syndrome reveals enhanced regional bone resorption and high bone turnover, and so bisphosphonates, which have a potent inhibitory effect on bone resorption, were proposed for the treatment of complex regional pain syndrome. Case presentation: A 48-year-old Japanese man with complex regional pain syndrome type I had severe right ankle pain with a visual analog scale score of 59 out of 100 regardless of treatment with physiotherapy and nonsteroidal anti-inflammatory drugs for five months. Radiographs showed marked regional osteoporotic changes and bone scintigraphy revealed a marked increase in radioactivity in his ankle. One month after the start of oral administration of risedronate (2.5 mg per day), his bone pain had fallen from a VAS score of 59 out of 100 to 18 out of 100. Bone scintigraphy at 12 months showed a marked reduction in radioactivity to a level comparable to that in his normal, left ankle. On the basis of these results, the treatment was discontinued at 15 months. At 32 months, our patient had almost no pain and radiographic findings revealed that the regional osteoporotic change had returned to normal. A second 48-year-old Japanese man with complex regional pain syndrome type I had severe right foot pain with a visual analog scale score of 83 out of 100 regardless of treatment with physiotherapy and nonsteroidal anti-inflammatory drugs for nine months. Radiographs showed regional osteoporotic change in his phalanges, metatarsals, and tarsals, and bone scintigraphy revealed a marked increase in radioactivity in his foot. One month after the start of oral administration of alendronate (35 mg per week), his bone pain had fallen from a visual analog scale score of 83 out of 100 to 30 out of 100 and, at nine months, was further reduced to 3 out of 100. The treatment was discontinued at 15 months because of successful pain reduction. At 30 months, our patient had no pain and the radiographic findings revealed marked improvement in regional osteoporotic changes. Conclusions: We believe low-dose oral administration of bisphosphonate is worth considering for the treatment of idiopathic complex regional pain syndrome type I accompanied by regional osteoporotic change.
- 4 August 2011
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 5 (1) , 349
Open AccessImprovement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series
Introduction: Complex regional pain syndrome is characterized by pain, allodynia, hyperalgesia, edema, signs of vasomotor instability, movement disorders, joint stiffness, and regional osteopenia. It is recognized to be difficult to treat, despite various methods of treatment, including physiotherapy, calcitonin, corticosteroids, sympathetic blockade, and nonsteroidal anti-inflammatory drugs. Pathophysiologically, complex regional pain syndrome reveals enhanced regional bone resorption and high bone turnover, and so bisphosphonates, which have a potent inhibitory effect on bone resorption, were proposed for the treatment of complex regional pain syndrome. Case presentation: A 48-year-old Japanese man with complex regional pain syndrome type I had severe right ankle pain with a visual analog scale score of 59 out of 100 regardless of treatment with physiotherapy and nonsteroidal anti-inflammatory drugs for five months. Radiographs showed marked regional osteoporotic changes and bone scintigraphy revealed a marked increase in radioactivity in his ankle. One month after the start of oral administration of risedronate (2.5 mg per day), his bone pain had fallen from a VAS score of 59 out of 100 to 18 out of 100. Bone scintigraphy at 12 months showed a marked reduction in radioactivity to a level comparable to that in his normal, left ankle. On the basis of these results, the treatment was discontinued at 15 months. At 32 months, our patient had almost no pain and radiographic findings revealed that the regional osteoporotic change had returned to normal. A second 48-year-old Japanese man with complex regional pain syndrome type I had severe right foot pain with a visual analog scale score of 83 out of 100 regardless of treatment with physiotherapy and nonsteroidal anti-inflammatory drugs for nine months. Radiographs showed regional osteoporotic change in his phalanges, metatarsals, and tarsals, and bone scintigraphy revealed a marked increase in radioactivity in his foot. One month after the start of oral administration of alendronate (35 mg per week), his bone pain had fallen from a visual analog scale score of 83 out of 100 to 30 out of 100 and, at nine months, was further reduced to 3 out of 100. The treatment was discontinued at 15 months because of successful pain reduction. At 30 months, our patient had no pain and the radiographic findings revealed marked improvement in regional osteoporotic changes. Conclusions: We believe low-dose oral administration of bisphosphonate is worth considering for the treatment of idiopathic complex regional pain syndrome type I accompanied by regional osteoporotic change.